The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
- 1 January 1996
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 49 (1), 209-216
- https://doi.org/10.1038/ki.1996.28
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Rapamycin Prolongs Survival and Arrests Pathophysiologic Changes in Murine Systemic Lupus ErythematosusArthritis & Rheumatism, 1994
- Effects of Orally Administered Rapamycin in Animal Models of Arthritis and Other Autoimmune DiseasesAnnals of the New York Academy of Sciences, 1993
- Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinasesCell, 1992
- SYNERGISTIC INTERACTIONS OF CYCLOSPORINE AND RAPAMYCIN TO INHIBIT IMMUNE PERFORMANCES OF NORMAL HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITROTransplantation, 1991
- RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG FOR VASCULARIZED HEART, KIDNEY, AND SMALL BOWEL TRANSPLANTATION IN THE RATTransplantation, 1991
- CyclosporineNew England Journal of Medicine, 1989
- RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTINGThe Lancet, 1989
- CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORSThe Lancet, 1978
- Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.The Journal of Antibiotics, 1978
- Inhibition of the immune response by rapamycin, a new antifungal antibioticCanadian Journal of Physiology and Pharmacology, 1977